
QUIDELORTHO CORP
QDELNASDAQTrading Snapshot
- Day Range
- $943.14 β $962.55
- 52-Week Range
- $9.92 β $35.58
- Volume
- $5.95B
- Avg Volume
- $7.51B
- Shares Outstanding
- 68.2M
- Next Earnings
- Aug 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.73B
- Last Q Revenue
- $631M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.4x
- EPS (TTM)
- $-15.35
- Dividend Yield
- 0.00%
Why Investors Own QDEL
- βHigh-growth profile β revenue up +36.5% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 17% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About QUIDELORTHO CORP
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
QUIDELORTHO CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift QDEL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
QUIDELORTHO CORP announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.